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INTRODUCTION
The skin is the largest organ in mammals. Skin has many im-
portant roles, including protection, maintenance of homeo-
stasis, thermoregulation, vitamin D synthesis, and sensory 
perception. Damage to the skin by trauma or surgery activates 
a series of interdependent and sequential physiological events 
involving inflammation, cell proliferation, matrix deposition, 
and remodeling for tissue repair. Excessive collagen production 
and deposition during wound healing cause abnormal dermal 
proliferation and the formation of hypertrophic scars. Hyper-
trophic scars often present with redness and itching as firm, 
rubbery lesions or shiny, fibrous nodules on the surface of the 
skin.1,2 
Various mechanisms have been proposed to explain the 
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pathogenesis of scars.3 However, treatment is difficult due in 
part to the lack of an accurate, practical, reproducible, and 
economical animal model with which to systematically study 
scar remodeling. Animal models are important for studying 
the complex interactions that occur in living tissue during 
wound healing without the limitations of in vitro techniques. 
Currently, many researchers use rodent models to study wound 
healing due to low costs, small animal size, and relative ease 
of handling and care. However, hypertrophic scars do not de-
velop in these species. In addition, the dermal composition of 
rodents does not resemble that of humans. In contrast, por-
cine skin is a good model for studying human dermal repair 
due to a number of similarities with human skin. Porcine and 
human skin has remarkably similar anatomies and physiolo-
gies, similar thicknesses of dermal and epidermal layers, and 
the presence of similar dermal appendages.4-7 In addition, ju-
venile domestic pigs can be used instead of adult swine to ad-
dress difficult handling and housing issues. Although juvenile 
animals tend to heal quicker than their older counterparts, 
the healing process takes a few months in juvenile pigs. Thus, 
sufficient time is available to assess the physiology and cellu-
lar biology of the healing process in a juvenile porcine model.8
The 6-kDa polypeptide hormone relaxin (RLX) is a member 
of the insulin family of peptides. RLX is primarily produced by 
the ovaries and/or placenta during pregnancy in mammals. 
RLX has multiple pregnancy-related functions, including con-
nective tissue remodeling in the reproductive tract and cervix 
during pregnancy and softening of the cervix and vagina at the 
time of delivery.9 Recent studies have demonstrated that RLX 
also has biological effects on the brain, heart, kidneys, lungs, 
and connective tissues independent of its roles in reproduc-
tion.10-12 These findings suggest that RLX may have therapeu-
tic applications for non-reproductive conditions, such as fibro-
sis. RLX may reduce fibrosis by suppressing collagen synthesis 
and increasing collagenase activity with subsequent collagen 
degradation.13-15
During the past 20 years, the field of virus-mediated gene 
therapy has grown tremendously. Adenoviruses (Ads)-based 
vectors, in particular, have attracted attention as gene-delivery 
vehicles due to their high titer capability and transduction effi-
ciency in both dividing and non-dividing cells.16,17 In this study, 
we introduced a RLX-expressing Ad vector (dE1-RGD/LacZ/
RLX) into scar tissue on the skin of a pig model. A previous in-
vestigation from our lab demonstrated that RLX-expressing 
Ad has potential therapeutic effects on keloid and hypertro-
phic scars due to the reversal of pathological fibrosis.18-20 How-
ever, a replication-incompetent Ad that expressed relaxin (Ad-
RLX) vector system was limited by immunogenicity, local 
inflammation, a short half-life, enzymatic inactivation, and tran-
sient effects, which resulted in short-term expression of RLX.21 
To address this problem, we tested a matrix-based depot sys-
tem with a biodegradable alginate gel, which is a natural poly-
mer frequently used in biomedical applications. Alginate gel 
can be used as a depot system for sustained release of Ad and 
maintenance of Ad viral activity due to its biocompatible envi-
ronment.22,23 Thus, the use of alginate gel should ultimately in-
crease therapeutic efficacy of RLX.
MATERIALS AND METHODS
Scar formation
The scar model was created with three Yorkshire pigs (XP Bio, 
Anseong, Korea; four months of age, 40 kg). Anesthesia was in-
duced in each pig via intramuscular injection of Zoletil (5 mg/
kg, Virbac, Carros, France) and Rompun (2 mg/kg, Bayer, Seoul, 
Korea). Hair was then completely removed from the backs and 
bellies of each pig. Inhalation anesthesia was achieved with 
isoflurane (IsoFlo, Abbott Laboratories, Abbott Park, IL, USA). 
After anesthetizing the pigs, 36 full-thickness skin defects (3×3 
cm2) were created symmetrically on the back of each York-
shire pig with 18 wounds on each side of the midline. Each 
wound reached the depth of the muscle fascia to mimic scar 
formation. The distance of each wound was maintained 5 cm 
in the horizontal direction and 3 cm in the vertical direction to 
control the interval of each scar (Supplementary Fig. 1, only 
online). Intravenous antibiotics and wound dressings with 
TegaDerm® (3M, St. Paul, MN, USA) were administered post-
operatively for 5 days, after which open dressings were main-
tained. Scar tissue, which was distinct in appearance from 
that of the peripheral normal tissue, formed at 50 days after 
creating the initial skin defect (Supplementary Fig. 2, only on-
line).7 The Animal Care and Experiment Committee of Yonsei 
University approved the experimental protocol (2011-0181).
Preparation of Ad and alginate gel
A replication-incompetent Ad that expressed relaxin (Ad-RLX) 
and control Ad (Ad-LacZ)18 was used in this study. The propa-
gation, purification, and titration of Ad were performed as 
previously described.24,25 An alginate (alginic acid sodium salt, 
Sigma, St. Louis, MO, USA) solution of 5 wt.% was prepared 
with 0.5 g of alginate and 0.09 g of NaCl (Sigma) in 10 mL of 
phosphate-buffered saline. The alginate solution was stirred 
for 24 h at room temperature and gelated at various concentra-
tions of CaCl2 (Sigma), ranging from 20 to 200 mM, to deter-
mine the optimal conditions for Ad transduction.
Injection of Ad into the pig scar model
Wound epithelialization and scar formation occurred on post-
operative day 50. Anesthesia was induced in each pig by intra-
muscular injection of Zoletil (5 mg/kg; Virbac) and Rompun 
(2 mg/kg; Bayer). Hair was then completely removed from the 
backs and bellies of each pig. Scars were divided into three 
groups (gel, gel/Ad-LacZ and gel/Ad-RLX). We injected 1 mL 
of alginate gel, the same amount of alginate gel encapsulating 
dE1-RGD/LacZ [5×107 plaque forming unit (PFU)], or alginate 
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gel encapsulating dE1-RGD/LacZ/RLX in each group respec-
tively. Injections were performed with a 27-gauge needle and 
1-mL syringe, and directly into the intradermal layers of the 
scar regions. 
Therapeutic evaluation of scar area, color index, and 
pliability
The surface areas of scars were imaged with a digital camera. 
The images of the surface areas of the scars were measured 
with a ruler and compared to a 1-cm2 standard. Measurements 
were assessed with Image J software (National Institutes of 
Health, Bethesda, MD, USA). The color of the scar was quanti-
tatively analyzed with a spectrophotometer (CM-700D; Konica 
Minolta, Inc., Tokyo, Japan). The color of each scar was exam-
ined with melanin (the degree of scar darkness) and erythema 
(the degree of scar redness) indices.26 Pliability was measured 
with a durometer (H1000 Mini-Dial, RexGauge Co., Buffalo 
Grove, IL, USA). Each value was measured more than three 
times, and the average value was calculated. All of the evalua-
tions were performed every 10 days until the 50th day after vi-
rus injection by the same individual who was blinded to the 
experimental group. Scar area, color index, and pliability were 
measured by an independent blinded physician.
Immunofluorescence microscopy
Specimens were collected at 10 days after the administration 
of the Ad virus and were embedded in paraffin blocks. Paraf-
fin-embedded tissues were sectioned, deparaffinized, hydrat-
ed, and treated with blocking buffer (20% normal goat serum, 
S-100, Vector Lab Inc., Burlingame, CA, USA) for one hour. Af-
ter removing the blocking buffer, sections were immersed in 
primary antibody (anti-relaxin, Santa Cruz Biotechnology, Dal-
las, TX, USA) overnight at 4°C and then incubated in second-
ary antibody (DyLight594, Vector Lab Inc.) at room temperature 
for 2 hours. The nucleus was stained with mounting solution 
containing DAPI. The degree of RLX expression in the tissue 
was evaluated by confocal microscopy (LSM700, Carl Zeiss, 
Oberkochen, Germany).
Arrangement of collagen fibers and mast cell count
Picrosirius red (Sigma-Aldrich Co., St. Louis, MO, USA) and 
toluidine blue (Sigma-Aldrich Co.) staining was performed on 
specimens 50 days after virus injection. Full thickness skin tis-
sues, 1×1 cm, were obtained from the center areas of scars 
and embedded in paraffin: we obtained 5 µm sections. Using 
the stained tissues, the number of mast cells (toluidine blue 
staining) and the collagen arrangement (picrosirius red stain-
ing) were compared using optical microscopy (BX51, Olym-
pus, Tokyo, Japan). The number of mast cells was counted in 
five different areas randomly chosen for each slide, and count-
ing was performed by magnifying images under ×100 magnifi-
cation.
Immunohistochemistry
Scar tissue sections were incubated at 4°C overnight with one 
of the following primary antibodies: mouse anti-collagen 
type-I (ab6308; Abcam, Ltd., Cambridge, UK), mouse anti-col-
lagen type-III (C7805; Sigma-Aldrich Co.), mouse anti-elastin 
(E4013; Sigma-Aldrich Co.), mouse anti-fibronectin (sc-52331; 
Santa Cruz Biotechnology), rabbit anti-transforming growth 
factor-β1 (anti-TGF-β1) (ab9758; Abcam, Ltd.), or mouse anti-
natural killer-1.1 (NK-1.1) antibody (108701; Biolegend, San 
Diego, CA, USA). Tissues were then incubated at room tem-
perature for 20 min with the DAKO EnvisionTM Kit (DAKO, 
Glostrup, Denmark) as a secondary antibody. Expression lev-
els of type-I and type-III collagens, elastin, fibronectin, 
TGF-β1, and NK-1.1 were semi-quantitatively analyzed with 
MetaMorph® image analysis software (Universal Image Corp., 
Buckinghamshire, UK). Results are expressed as the mean op-
tical density of six different digital images. Immunohisto-
chemistry was performed by the same individual who was 
blinded to the experimental group, and the tissue sections for 
analysis were obtained from the center areas of scar tissue.
Real-time reverse transcriptase-polymerase chain 
reaction for expression of TGF-β1 and TGF-β3 mRNAs
Scar tissues were treated with gel, gel/Ad-LacZ, or gel/Ad-RLX 
at 5×107 PFU of Ad. On the injection date and 50 days post-
treatment, cDNA was synthesized with AccuPowerTM RT Pre-
Mix (Bioneer, Daejeon, Korea) after extracting total RNA with 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). PCR was per-
formed in a 20-μL reaction volume containing the synthesized 
cDNA and 2× Taq Premix (Solgent, Daejeon, Korea). Thermal 
cycling was performed initially for 5 min at 94°C, followed by 
30 cycles of 30 sec at 94°C, 30 sec at 58°C, and 30 sec at 72°C, 
and finally 5 min at 72°C. After electrophoresis on a 1% agarose 
gel, each band was evaluated by densitometry (Image J, Na-
tional Institutes of Health). The standard value (β-actin) was 
converted to 1, and analyses were performed by obtaining the 
ratio with the other measured values [TGF-β1 (Ss03382325, 
ThermoFisher Scientific, MA, USA) and TGF-β3 (Ss03394349, 
ThermoFisher Scientific)]. PCR was performed three times for 
each mRNA in each tissue, and the average value was calcu-
lated.
Statistical analysis
All test results are presented as a mean±standard error of the 
mean. The results of quantitative analyses were statistically 
analyzed in three groups by one-way ANOVA and the multi-
ple-comparison Bonferroni correction method. A p value less 
than 0.05 was considered statistically significant. Statistical 
analyses were performed with SAS software (version 9.1.3, SAS 
Institute Inc., Cary, NC, USA).
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RESULTS
Relaxin-expressing Ad decreases scar size, color 
index, and pliability in pig scar tissue
Scars with full thickness were generated on the backs of York-
shire pigs. An RLX-expressing Ad vector entrapped in alginate 
gel was evaluated for effects on scar remodeling. The sizes of 
the initial scars were 3.15±0.15 cm2, 3.12±0.11 cm2, and 3.18± 
0.08 cm2 in the gel, gel/Ad-LacZ, and gel/Ad-RLX groups, re-
spectively. Alginate gel (gel), alginate gel encapsulating dE1-
RGD/LacZ (gel/Ad-LacZ), or alginate gel encapsulating dE1-
RGD/LacZ/RLX (gel/Ad-RLX), respectively, was injected into 
the scar tissue. The sizes of the scars decreased to 1.61±0.15 
cm2, 1.70±0.10 cm2, and 1.37±0.05 cm2 in each group, respec-
tively, by 50 days after treatment (Fig. 1A and B, Supplementa-
ry Fig. 3, only online). These results indicated that RLX expres-
sion from Ad (gel/Ad-RLX) reduces the size of scars compared 
to those of the control groups (gel or gel/Ad-LacZ) (p<0.05; 
Fig. 1B).
To further examine the effect of RLX on scar remodeling, 
color changes and pliability were investigated by spectropho-
tometry in conjunction with erythema and melanin indices 
and a durometer. The erythema index values of the initial scars 
were 1.97±0.20, 2.01±0.10, and 2.01±0.09 in the gel, gel/Ad-
LacZ, and gel/Ad-RLX groups, respectively. Erythema was 
significantly reduced (1.52±0.15; p<0.05) in the gel/Ad-RLX 
group at 50 days after treatment, compared to those in the gel 
(2.07±0.35) and gel/Ad-LacZ (2.05±0.08) groups (Fig. 1C). The 
initial melanin index values were 0.23±0.06, 0.23±0.02, and 
0.23±0.03 in the gel, gel/Ad-LacZ, and gel/Ad-RLX groups, re-
spectively (Fig. 1D). This index was also significantly (p<0.05) 
decreased to 0.08±0.02 in the gel/Ad-RLX group, compared to 
0.21±0.05 and 0.21±0.04 in the gel and gel/Ad-LacZ control 
groups, respectively, at 50 days after treatment. Similarly, pli-
ability was significantly (p<0.05) reduced in the gel/Ad-RLX 
group, compared to the gel and gel/Ad-LacZ control groups (Fig. 
1E). The initial scars had pliability measurements of 20.50±1.42, 
19.73±0.88, and 19.08±1.06 in the gel, gel/Ad-LacZ, and gel/
Ad-RLX groups, respectively. Pliability was reduced to 18.00± 
0.58, 17.46±1.62, and 11.15±1.72 in the gel, gel/Ad-LacZ, and 
gel/Ad-RLX groups, respectively, by 50 days after treatment. 
Taken together, these data suggested that RLX expression 
from gel/Ad-RLX promotes the remodeling of scar tissue.
Relaxin-expressing Ad induces collagen 
rearrangement and decreases expression of major 
ECM components in scar tissue
We examined RLX expression by immunofluorescence stain-
ing in pig scar tissues transduced with gel, gel/Ad-LacZ, or 
gel/Ad-RLX. The gel/Ad-RLX-treated groups showed mark-
edly increased immunoreactivity for RLX, compared to the 
control groups (gel or gel/Ad-LacZ). These results confirmed 
an association between increased RLX expression and reduced 
scar tissue formation in tissues transduced with the gel/Ad-
RLX depot system (Fig. 2).
To evaluate the effects of RLX-expressing Ad on collagen-fi-
ber arrangement, tissues were stained with picrosirius red, 
which binds specifically to collagen fibrils of various diame-
Fig. 1. Relaxin (RLX) expression reduces the size, color index, and pliability of pig scars. (A) Scars were created on the backs of pigs. The area of scars 
decreased, and the color improved at 50 days after the injection of relaxin-expressing Ad loaded in alginate gel (gel/Ad-RLX). (B) Scar size, (C) erythema 
index values, (D) melanin index values, and (E) pliability were significantly reduced (†p<0.05) compared to those of control groups [gel or LacZ-expressing 
Ad loaded in alginate gel (gel/Ad-LacZ)]. Data are expressed as a mean±standard error of the mean.
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ters. The gel/Ad-RLX-treated groups had closely packed colla-
gen fibers and formed bundles of collagen (Fig. 3A), com-
pared to those in the control groups (gel or gel/Ad-LacZ). These 
data suggested that RLX induces collagen rearrangement to 
resemble that of mature, bundle-shaped collagen fibers.
We next examined the effects of RLX overexpression on the 
major extracellular matrix (ECM) components of scar tissues. 
Immunohistochemical staining of scar sections revealed sig-
nificant reductions in type-I collagen, type-III collagen, elastin, 
and fibronectin in the gel/Ad-RLX-treated group, compared 
with those in the gel/Ad-LacZ group (p<0.01) (Fig. 3B-F). These 
data strongly suggested that expression levels of the major 
ECM components were significantly decreased by RLX over-
expression in pig scar tissues. Moreover, these results implied 
that RLX can play a prominent role in ECM remodeling during 
the development of scar tissue.
Relaxin-expressing Ad increases MMP-1 and decreas-
es TIMP-1 and α-SMA expression in pig scar tissue
Matrix metalloproteinase-1 (MMP-1), tissue inhibitor of me-
talloproteinase-1 (TIMP-1), and alpha-smooth muscle actin 
(α-SMA) are important markers of the effects of TGF-β on 
wound repair. Therefore, we performed immunohistochemistry 
to examine expression of MMP-1, TIMP-1, and α-SMA. MMP-1 
expression levels were significantly increased by 7.0-fold in pig 
scar tissues treated with gel/Ad-RLX versus that of the gel/Ad-
LacZ-treated tissues (p<0.01) (Fig. 4). In contrast, TIMP-1 and 
α-SMA expression levels were significantly decreased by 1.9-
and 9.9-fold, respectively, in pig scar tissues treated with gel/
Ad-RLX transduction (p<0.05). These results suggested that 
RLX upregulates MMP-1 and downregulates TIMP-1 and 
α-SMA, which are major players in collagen breakdown.
Fig. 2. Immunofluorescence staining to evaluate the effects of relaxin on scar reduction in pig scar tissues. Increased expression of relaxin was de-
tected after treatment with relaxin-expressing Ad loaded in alginate gel (gel/Ad-RLX). In contrast, control groups [gel or LacZ-expressing Ad loaded 
in alginate gel (gel/Ad-LacZ)] showed lower levels of relaxin. Nuclei were visualized by DAPI (4',6-diamidino-2-phenylindole) staining; original magni-
fication, ×400; scale bar=20 µm.
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Relaxin-expressing Ad downregulates TGF-β1 and 
upregulates TGF-β3 expression in pig scar tissue
To examine the mechanism by which RLX-expressing Ad sup-
presses expression of the major ECM components, TGF-β1 
and TGF-β3 mRNA levels were examined in scar tissues. The 
gel/Ad-RLX group showed decreased TGF-β1 mRNA expres-
sion and increased TGF-β3 mRNA expression in scar tissues, 
compared with those in the gel or gel/Ad-LacZ group (Fig. 5) 
(p<0.05), suggesting that the reduced expression of ECM com-
ponents by RLX overexpression is associated with decreased 
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Fig. 3. Picrosirius red staining and immunohistochemical staining for collagen type-I, collagen type-III, elastin, and fibronectin in pig scar tissues. (A) 
Dense and coarse collagen fibers were replaced with closely packed collagen fibers after pig scar tissues were treated with gel/Ad-RLX; original 
magnification, ×100 and ×200; scale bar=500 µm and 200 µm. (B) The expression levels of the major extracellular matrix components collagen type-I, 
collagen type-III, elastin, and fibronectin were lower in pig scar tissues treated with gel/Ad-RLX than those in pig tissues treated with gel or gel/Ad-
LacZ; original magnification, ×400; scale bar=100 µm. Semi-quantitative image analyses revealed that (C) collagen type-I, (D) collagen type-III, (E) 
elastin, and (F) fibronectin were significantly decreased in pig tissues treated with gel/Ad-RLX, compared to those in pig tissues treated with control 
virus (*p<0.01). Data are expressed as a mean±standard error of the mean.
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expression of TGF-β1 and increased expression of TGF-β3.
We also checked TGF-β1 expression via immunohistochem-
ical staining of the scar sections. The results revealed signifi-
cant reductions in TGF-β1 in the gel/Ad-RLX-treated group, 
compared to the gel/Ad-LacZ group (p<0.05) (Supplementary 
Fig. 4, only online).
Relaxin-expressing Ad decreases mast cell counts and 
NK-1.1 expression in pig scar tissue
Mast cells are reported to be involved in the proliferation and 
contraction of fibroblasts, and the synthesis of ECM. They also 
play a key role in scar formation. The amount of mast cells was 
increased by four times in hypertrophic scars than in normal 
skin.27-29 To examine the local inflammatory effects of RLX-ex-
pressing Ad, mast cell counts and NK-1.1 immunohistochem-
istry were assessed. Immediately after scar formation, the mean 
numbers of mast cells were 6.20±1.30, 7.00±0.80, and 6.30± 
0.70 in the gel, gel/Ad-LacZ, and gel/Ad-RLX groups, respec-
tively, with no significant differences. Fifty days after injection of 
the virus, the mean numbers of observed mast cells were 6.80± 
0.42 in the gel group and 7.09±0.68 in the gel/Ad-LacZ group. 
A significant decrease was seen in the mean number of mast 
cells in the gel/Ad-RLX group (4.89±0.40; p<0.01; Supplemen-
tary Fig. 5, only online). NK-1.1 expression was significantly 
lower in the gel/Ad-LacZ and gel/Ad-RLX-treated groups, 
compared to the gel group (p<0.05) (Supplementary Fig. 6, 
only online).
DISCUSSION
Scars, which are caused by collagen deposition, confer a large 
number of functional problems. Nowadays, many patients want 
to minimize scar formation, and many treatment modalities, 
such as scar revision, laser therapy, and medications, have 
been applied to prevent scar formation. However, the suc-
cessful treatment of scars has not been fully resolved.30-32
This study was performed by adopting a pig scar model used 
our previous study. The aim of this study was to verify the anti-
fibrotic effect of RLX on scars. Recent studies supported our 
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Fig. 4. Immunohistochemical staining for matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1), and alpha-smooth mus-
cle actin (α-SMA) in pig scar tissues. (A) Treatment with gel/Ad-RLX markedly increased MMP-1 levels and decreased TIMP-1 and α-SMA levels in pig 
scar tissues; original magnification, ×400; scale bar=100 µm. Semi-quantitative image analyses revealed that (B) MMP-1 was significantly increased in 
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data and suggested that RLX exerts alternative biological effects 
mediated directly through TGF-β-dependent signaling.14,18,19,30-32 
These effects elicit downregulation of TGF-β1 and upregula-
tion of TGF-β3 to inhibit myofibroblast accumulation, colla-
gen synthesis/secretion, and ultimately, fibrosis progression 
in scar tissue. Other studies have suggested that TGF-β1 is a 
potent fibrogenic growth factor, whereas TGF-β3 reduces scar 
tissue by decreasing synthesis and increasing degradation of 
type-I collagen.33 TGF-β plays a key role in the pathophysiolo-
gy of fibroplasia by decreasing the expression of MMPs and in-
creasing the expression of TIMPs.19 
Furthermore, TGF-β induces α-SMA expression, implying 
that α-SMA expression is a marker of TGF-β activity.32-37 Thus, 
the increased expression of MMP-1 and decreased levels of 
TIMP and α-SMA suggest that dE1-RGD/LacZ/RLX plays a 
prominent role in ECM remodeling in hypertrophic scars. 
MMP-1 promotes degradation and ECM remodeling, whereas 
TIMP-1 decreases the activities of plasminogen activators, 
such as MMPs, and shifts the ECM equilibrium toward degra-
dation. Thus, increased MMP-1 production and decreased 
TIMP-1 expression should reduce the amount of abnormal or 
unfolded collagen during wound healing. In addition, reduced 
levels of α-SMA may be a positive indicator of TGF-β activity, 
which was decreased in the gel/Ad-RLX group in this study. 
Taken together, these studies suggest that dE1-RGD/LacZ/
RLX is a potential therapeutic intervention for hypertrophic 
scars.
Ad has been used extensively as a gene-delivery system in 
experimental models of cancer and cardiovascular diseases.38-40 
However, one of the chief concerns with translating these ex-
perimental results to the clinical setting is the large and re-
peated dose that is usually required to generate a modest clin-
ical effect or to achieve the desired therapeutic concentration 
at the target. To address this concern, we utilized an Arg-Gly-
Asp-modified (RGD) replication-incompetent Ad vector as a 
strategy to allow direct delivery of the RLX gene to wounds. 
Previous studies from our lab showed that RGD-modified Ad 
markedly increases gene transfer efficiency in primary keloid 
fibroblasts. Thus, we believe that RGD-modified Ad is a highly 
efficient gene-transfer vehicle that does not adversely affect 
the replication potential of target cells.14,17
To further advance this potential therapy for hypertrophic 
scars, we generated and characterized an alginate gel-matrix 
system to entrap RLX-expressing Ad as a delivery vehicle.22,23 
Previous studies have indicated that the biological activity of 
Ad loaded in alginate gel is prolonged, compared with that of 
naked Ad, over an extended period of time. Cells that were 
transduced with gel-released Ad expressed green fluorescence 
protein at a 13-fold greater intensity at seven days post-incuba-
tion compared to that of naked Ad. Because long-term trans-
duction is needed for in vivo applications, the Ad/alginate gel 
may be very useful as a depot system. The Ad/alginate gel acts 
as a reservoir that releases Ad in a sustained manner and 
maintains the biological activity of Ad. Alginate gel has also 
been shown to limit the mobility of Ad by entrapping Ad with-
in its scaffold, further minimizing the spread of the replica-
tion-incompetent Ad outside of the scar tissue. These results 
show that sustained and controlled delivery of Ad in alginate 
gel markedly augments therapeutic effects, prolongs mainte-
nance of Ad activity, and provides specificity for local delivery 
of replication-incompetent Ad at high concentrations. These 
advantages of the Ad/alginate system will allow for potent lo-
cal viral therapy to a target site.
In conclusion, we provide strong evidence that RLX pro-
motes the remodeling of scar tissue. Moreover, sustained and 
controlled delivery of Ad in alginate gel markedly augments 
the therapeutic effects of RLX. Our data support further evalu-
ation of gel/Ad-RLX as a novel gene-therapy system for treat-
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ing human scars.
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